Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GABRP | O00591 | 3/20 | 0.39 |
| ▸ | GABRD | O14764 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | GABRE | P78334 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958518 | 0.87 | PDE2A (0.44) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL21139491 | 0.87 | PDE2A (0.44) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL24986404 | 0.86 | PDE2A (0.43) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL24986405 | 0.86 | PDE2A (0.43) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL24985335 | 0.82 | PDE2A (0.41) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL24986389 | 0.82 | PDE2A (0.41) | PDE2AGABRA2GABRB2GABRB3ALDH1A1 | |
| SCHEMBL8561738 | 0.82 | PDE2A (0.61) | PDE2ASMN1; SMN2GABRA2GABRB2ALDH1A1 | |
| SCHEMBL13748819 | 0.81 | AR (0.47) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL24985333 | 0.80 | PDE2A (0.39) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 | |
| SCHEMBL18638714 | 0.79 | PDE2A (0.44) | PDE2ASMN1; SMN2GABRA2GABRB2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | DOW AGROSCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149557-A1 | CXCR3 antagonists | AMGEN INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | PDE2A 4631/4885SMN1; SMN2 2699/4885GABRA2 2729/4885 |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PDE2A 3597/4885SMN1; SMN2 3741/4885GABRA2 1824/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PDE2A 3597/4885SMN1; SMN2 3741/4885GABRA2 1824/4885 |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | PDXK, DPYD, DDT | PDE2A 2216/4885SMN1; SMN2 3265/4885GABRA2 576/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | PDE2A 3427/4885SMN1; SMN2 3882/4885GABRA2 2243/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PDE2A 3597/4885SMN1; SMN2 3741/4885GABRA2 1824/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PDE2A 3597/4885SMN1; SMN2 3741/4885GABRA2 1824/4885 |
| US-20070149557-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | PDE2A 2737/4885SMN1; SMN2 4118/4885GABRA2 601/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | PDE2A 4637/4885SMN1; SMN2 2223/4885GABRA2 2785/4885 |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | DDT, ACHE, AHR | PDE2A 333/4885SMN1; SMN2 4164/4885GABRA2 3089/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PDE2A 3597/4885SMN1; SMN2 3741/4885GABRA2 1824/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | PDE2A 2935/4885SMN1; SMN2 3556/4885GABRA2 3155/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | PDE2A 2935/4885SMN1; SMN2 3556/4885GABRA2 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.